BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
BioAge Labs, Inc.NASDAQ: BIOA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $63K rose 70.3% year over year, ahead of the +39.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 8.7% from the prior quarter. Over 3 fiscal years it compounded at +18.2% a year.
Context
- Depreciation & amortization amounted to 2.4% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +70.3% holds above the trailing-twelve-month pace of +39.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 213K USD
- Year-over-year change
- +27.5%
- 3-year CAGR
- +18.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 213K | +27.5% |
| FY2024 | 2024-12-31 | 167K | +3.1% |
| FY2023 | 2023-12-31 | 162K | +25.6% |
| FY2022 | 2022-12-31 | 129K | — |
Depreciation & Amortization vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.8% is the highest of 9, against a peer median of -7.9%.
- Depreciation & amortization amounts to 2.3% of revenue for BIOA, versus a peer median of 11.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$39.79M CAD | -7.7% | -14.0% | 12.7% | |
| LTM Mar 2026 | CA$14.19M CAD | -37.1% | -31.1% | 4.6% | |
| LTM Mar 2026 | $12.13M USD | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $9.76M USD | — | -23.7% | 7.2% | |
| LTM Mar 2026 | $6.86M USD | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $6.34M USD | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $4.17M USD | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $1.5M USD | -16.9% | +11.8% | — | |
| LTM Mar 2026 | $416K USD | +0.0% | +17.0% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| Peer median (excluding BIOA) | — | -7.9% | -5.9% | 11.8% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.